Nimodipine

General description Malononitrile, a weak cyanocarbon acid, is a versatile compound with exceptional reactivity. This crystalline aliphatic nitrile is used as a building block to synthesize heterocyclic compounds and polymers Application

General description Malononitrile, a weak cyanocarbon acid, is a versatile compound with exceptional reactivity. This crystalline aliphatic nitrile is used as a building block to synthesize heterocyclic compounds and polymers Application

General description Malononitrile, a weak cyanocarbon acid, is a versatile compound with exceptional reactivity. This crystalline aliphatic nitrile is used as a building block to synthesize heterocyclic compounds and polymers Application

Niludipine.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description Nimodipine is a well-known calcium antagonist and is a moderate cerebral vasodilator, in addition to being an inhibitor of cerebrovascular reactivity. It is suggested to be cytoprotective by causing a decrease in the influx of

Application Nimodipine has been used: as a L-type calcium channel (LTCC) inhibitor, to evaluate its neuroprotective activity in the vibrosections as a standard, in the enantioseparation of chiral drugs by high performance liquid chromatography

Application Nimodipine has been used: as a L-type calcium channel (LTCC) inhibitor, to evaluate its neuroprotective activity in the vibrosections as a standard, in the enantioseparation of chiral drugs by high performance liquid chromatography

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

An antagonist of L-type voltage-dependent Ca2+ channels (Ki = 5.3 nM) inhibition is voltage dependent reduces the impact of delayed ischemic neurological deficits following subarachnoid hemorrhage.